What Is AmnioFill?
AmnioFill is a placenta-based tissue matrix in a particulate configuration to replace or supplement damaged or inadequate integumental tissue in acute and chronic closures in comorbid patients.
Versatile Tissue Form
- Replaces or supplements damaged or inadequate integumental tissue
- Provides a human biocompatible extracellular matrix
Retains Regulatory Proteins
300+ regulatory proteins1-3
Product Advantages
- SMR2T™ Technology and patented Purion® processing
- Terminally sterilized for additional level of safety
- Easy to apply
- Room temperature storage
- 5-year shelf life
- Compatible with negative pressure wound therapy (NPWT) and hyperbaric oxygen therapy (HBO)
Clinical Use Examples
- Comorbid patients with complex defects or delayed healing
- Diabetic foot ulcers (DFUs)
- Venous leg ulcers (VLUs)
- Debridements
- Decubitus ulcers
Product Details
AmnioFill is processed using Purion, a unique patented method for placental-based allografts that is in accordance with the American Association of Tissue Banks (AATB) standards. The product is derived from donated C-sections of live births in the US. The product undergoes active preservation of the extracellular matrix (ECM), regulatory proteins, and removal of blood contaminants via a proprietary cleansing process. For an additional level of safety, the product is terminally sterilized.
AmnioFill is SMR2T Technology (Selective Membrane of Reparative and Reconstructive Tissue)
1. Koob, et al. J Biomed Mater Res B Appl Biomater. 2014 Aug;102(6):1353-62. 2. Lei, et al. Adv Wound Care. 2017 Feb 1;6(2):43-53. 3. MM-RD-00086, Proteome Characterization of Purion Processed Dehydrated Human Amnion Chorion Membrane (dHACM) and Purion Plus Processed Dehydrated Human Umbilical Cord (dHUC) Allografts.
